Drug profile

The FDA adverse-event record for Gentamyc/Betam Acet Eye Drops

18 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Gentamyc/Betam Acet Eye Drops. See the species affected, top reactions, and outcomes below.

18
adverse-event reports
11.1%
death-coded share
Unknown
most-reported species
4
Eye redness - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
18
Total Reports
2
Deaths Reported
11.1%
Death Rate

Active Ingredients

Gentamyc/Betam Acet Eye Drops

Administration Routes

UnknownOphthalmicAuricular (Otic)

Species Affected

Unknown 6
Dog 6
Cat 3
Human 3

Most Affected Breeds

Unknown 9
Domestic Shorthair 2
Terrier - Boston 1
Dachshund (unspecified) 1
Pit Bull 1
Cat (unknown) 1
Crossbred Canine/dog 1
Terrier - Yorkshire 1
Dog (unknown) 1

Most Reported Reactions

Eye redness 4
Product problem 3
Vomiting 3
Eye disorder NOS (for photophobia see 'neurological') 3
Uncoded sign 2
Containers, Leaking 2
Vocalisation 2
Appearance, Abnormal 2
Closure, Abnormal 2
Lethargy (see also Central nervous system depression in 'Neurological') 2
Accidental exposure 2
Caps, Abnormal 1

Outcome Breakdown

Ongoing
5 (41.7%)
Recovered/Normal
3 (25.0%)
Outcome Unknown
2 (16.7%)
Died
1 (8.3%)
Euthanized
1 (8.3%)

Gentamyc/Betam Acet Eye Drops Adverse Event Insights

18 reports name Gentamyc/Betam Acet Eye Drops; 2 recorded a death outcome (11.1% of reported events, not a population-level mortality rate). Active ingredient: Gentamyc/Betam Acet Eye Drops. Administration routes: Unknown, Ophthalmic, Auricular (Otic).

By species: Unknown (6 reports), Dog (6 reports), Cat (3 reports). By breed: Unknown (9), Domestic Shorthair (2), Terrier - Boston (1).

Leading clinical signs: Eye redness (4), Product problem (3), Vomiting (3), Eye disorder NOS (for photophobia see 'neurological') (3). Outcome, 12 coded reports: Ongoing leads at 41.7%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.